News for ImmunityBio, Inc. (IBRX)

ImmunityBio’s Anktiva holds bladder cancer promise despite FDA hurdles, while its lymphopenia treatment could unlock major upside. Learn why IBRX stock is a buy.

We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ImmunityBio, Inc.

We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other Wednesday’s best-performing stocks. ImmunityBio extended its winning streak to a fifth consecutive day on Wednesday, jumping 8.1 percent to finish at $2.93 apiece […]

On June 4, 2025, noted analyst Andres Maldonado of HC Wainwright & Co. reaffirmed the

Summary ImmunityBio Inc (IBRX) announced groundbreaking results at the ASCO 2025 conference, showcasing the first known treatment for lymphopenia using ANKTIVA

ImmunityBio's ANKTIVA (IBRX) demonstrates significant survival benefits in advanced pancreatic cancer. The treatment targets lymphopenia, showing improv

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-

In a recent report dated June 3, 2025, ImmunityBio (IBRX) continues to be under the spotlight as D. Boral Capital, led by analyst Jason Kolbert, maintained its

Key Takeaways: ImmunityBio Inc. (IBRX) has secured FDA approval for expanded access to its innovative Cancer BioShield platform, focusing on aggressive tumo

FDA approves expanded access for ImmunityBio's Anktiva to treat lymphopenia in advanced solid tumor patients.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the ”œCompany” or ”œHCW Biologics”) ( HCWB), a clinical-stage biopharmaceutical comp

ImmunityBio, Inc. (IBRX) faces a setback due to the FDA's Refusal to File (RTF) letter. Analyst projections show a significant upside potential for IBRX

ImmunityBio, Inc.'s FDA rejection for ANKTIVA impacts IBRX shares. Explore the market reaction, potential catalysts, and investment strategy. Click for my update.

ImmunityBio (IBRX) encountered a challenge as the FDA issued a refusal to file letter for the company's supplemental application of Anktiva in combination with

Key Highlights:\n ImmunityBio's QUILT-3.032 study shows significant effectiveness in treating bladder cancer. Analyst forecasts suggest considerable upside

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Monday. Shares of Netflix, Inc. (NASDAQ: NFLX fell sharply in tod...

ImmunityBio (IBRX) has encountered an obstacle with the U.S. FDA, as the agency issued a Refusal to File letter for the company's supplemental biologics license

\n ImmunityBio (IBRX) has requested an urgent meeting with the FDA after receiving a Refusal to File (RTF) letter for their supplemental biologics license app